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Abstract
Background: Since the classic Hopkins and Groom druggable genome review in 2002, there have been a number
of publications updating both the hypothetical and successful human drug target statistics. However, listings of
research targets that define the area between these two extremes are sparse because of the challenges of
collating published information at the necessary scale. We have addressed this by interrogating databases,
populated by expert curation, of bioactivity data extracted from patents and journal papers over the last 30 years.
Results: From a subset of just over 27,000 documents we have extracted a set of compound-to-target
relationships for biochemical in vitro binding-type assay data for 1,736 human proteins and 1,654 gene identifiers.
These are linked to 1,671,951 compound records derived from 823,179 unique chemical structures. The distribution
showed a compounds-per-target average of 964 with a maximum of 42,869 (Factor Xa). The list includes non-
targets, failed targets and cross-screening targets. The top-278 most actively pursued targets cover 90% of the
compounds. We further investigated target ranking by determining the number of molecular frameworks and
scaffolds. These were compared to the compound counts as alternative measures of chemical diversity on a per-
target basis.
Conclusions: The compounds-per-protein listing generated in this work (provided as a supplementary file)
represents the major proportion of the human drug target landscape defined by published data. We
supplemented the simple ranking by the number of compounds assayed with additional rankings by molecular
topology. These showed significant differences and provide complementary assessments of chemical tractability.
Introduction
An important factor in assessing the global progress in
drug research is the number of targets for which thera-
peutic small-molecule modulators have been, are being,
or could be, generated. This question was addressed in
the landmark publication in 2002 that introduced the
“druggable genome” concept [1].
This total of approximately 3,000 human proteins was
arrived at by homologous family extrapolation from the
targets of approved drugs at that time. The count of
successful targets was updated in 2006 and stood then
at 324, of which the subset of human proteins was 207
[2]. Despite many publications covering this topic, the
inclusion of explicit listings of target identifiers, extrinsic
to the data sets from which they were derived, are rare,
with the partial exception of a poster that included 185
human targets of approved oral drugs [2].
Notwithstanding, there are now public databases from
which it is possible to browse and extract targets with
explicit links to bioactive compounds. DrugBank is one
such resource [3]. It has a total of 6,827 drug entries
including 1,431 FDA-approved small molecule drugs
and 5,212 research compounds linked to 4,477 non-
redundant protein sequences. These include primary
targets, cross-screening targets, metabolising enzymes
and associations inferred from compound name with
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from the literature. The Therapeutic Targets Database
(TTD) contains conceptually similar information to
DrugBank but organised into a different data structure
[4]. It provides sequence subsets of their total of 1,675
targets divided into 348 approved, 260 clinical trial and
1,067 research targets. The BindingDB resource also
includes approved and research targets with a focus on
measured small-molecule binding affinities and ligands.
It currently includes 5,526 protein targets and 271,419
compounds [5]. The largest public resource of this type
is the ChEMBL database with 8,091 targets and 658,075
compounds extracted from medicinal chemistry journal
papers (N.B. a subset of ChEMBL data is now incorpo-
rated into BindingDB) [6]. Three of the databases above,
DrugBank, TTD and ChEMBL, have recently been
included in a comparative study of compounds and tar-
gets [7].
Databases and Processing
The company GVKBIO [8] has developed a suite of
databases over the last 9 years that are now unified
under a single query interface, termed GVKBIO Online
Structure Activity Relationships (GOSTAR) [9,10]. The
results we present are from two of the six GOSTAR
components, the Medicinal Chemistry (MCD) and Tar-
get (TGD) Databases. Their combined utility for mining
drug research data has already been described [11-14].
In addition, the comparison of compound and target
content of these with other bioactivity databases has
been reported in publications that included the expan-
sion of coverage between 2006 and 2008 [15,16].
The data in MCD and TGD are derived from the
large-scale expert extraction of structure-activity rela-
tionships (SAR) from patents and journal papers report-
ing the results of drug discovery research [9]. The basic
process is familiar to scientists working in this area. By
inspecting a document “D” they can identify the descrip-
tion of a biochemical assay “A” (e.g. for enzyme activity)
with a quantitative result “R” (e.g. a Ki) for a compound
“C” (e.g. a specific chemical structure) that defines it as
an activity modulator (e.g. an inhibitor) of protein target
“P” (e.g. a protease). An outline of these relationships is
shown in Figure 1.
At GVKBIO the relationships between these five enti-
ties of document, assay description, assay result, com-
pound structure and protein target (D-A-R-C-P) are
manually abstracted by a team of expert curators and
transferred to document-centric relational databases.
These contain data predominantly from the research
phases of drug discovery but, because this extends back
over 30 years, much of the primary data for approved
drugs is included. The difference between them is that
MCD extracts data from 120 journals selected for their
high content of D-A-R-C-P relationships on a per-jour-
nal basis. TGD extracts the same relationships from
patents covering the “big ten” target classes (kinases,
GPCRs, proteases, nuclear hormone receptors, ion-chan-
nels, transporters, lipases, phosphatases, oxidoreductases
and transferases). The process involves a triage to select
a representative of the patent family for extraction. The
addition of compounds to the database is limited to
exemplified structures linked to quantitative or qualita-
tive assay data. While all structures with quantitative
results are extracted, where the activity data is ranged
or only qualitative, the number of compounds extracted
is capped at 200 or 100 examples, respectively [10].
Details of these databases are described elsewhere but
briefly, structures and related metadata for the GOSTAR
database records are stored in an Oracle database [17].
The compound counts are defined by a unique structure
identifier based on the Standard InChIKey [18]. Protein
Figure 1 Depiction of the key entities and the relationships between them (D-A-R-C-P) used to populate the MCD and TGD databases.
Southan et al. Journal of Cheminformatics 2011, 3:14
http://www.jcheminf.com/content/3/1/14
Page 2 of 11information was added using NCBI Entrez Gene as pri-
mary source for protein (gene) names and identifiers
(EGID) [19]. Where documents specified distinct alter-
native splice forms in assays, the common name used by
the authors for that splice form was included with the
EGID.
Target classes were assigned according to an internal
schema. GVKBIO internally developed tools were also
used to generate frameworks, scaffolds, and graph skele-
tons. The data was mined by running SQL queries
against MCD and TGD subsets of the GOSTAR data-
base. Additional filters were species, targets having an
Entrez Gene name and assay type. Tables and graphs
were generated in Excel.
Results and Discussion
The content statistics of the aggregated MCD and TGD
sources, with combined and separate numbers for
patents and journal papers, are shown in Table 1.
The following aspects can be expanded. The average
redundancy (records-per-unique structure) is 1.5
because some compounds, particularly reference
reagents and established drugs, have assay data included
in many documents. The predominant assay type is
termed “type-B” or binding assay because it encom-
passes the enzyme inhibition and receptor binding
assays most commonly reported for compounds tested
against molecular targets in vitro and, implicitly, with
binding specificity. The last three rows show the strin-
gency used to define the final target listing. The target
names in row 12 encompass both defined and undefined
molecular targets (e.g. protein complexes or unresolved
subfamilies) that are linked to compounds via a type-B
assay result. These are further restricted in row 13 to
only those molecular targets mapping to a protein iden-
tifier (e.g. an Entrez Gene ID or a Swiss-Prot accession).
We added a final restriction to human sequences (row
14). We made this simplification choice for two reasons.
The first was to exclude the many proteins used as
cross-screening targets from mouse, rat and other
model organisms. The second reason is that resolving
anti-infective molecular target protein IDs also comes
up against the problem of orthologous redundancy due
to the multiplicity of viral, as well as bacterial sub-types,
strains and species.
Counting Distinct Human Protein Targets
We used the MCD and TGD databases to compile a list
of all human gene identifiers that were linked with com-
pounds via the results of type-B assays. The full list of
these protein sequence identifiers, compound counts
and document counts is included in Additional file 1,
with the target statistics in Table 2.
To maximise the curatorial specificity of mapping com-
pounds to protein sequences, a number of splice form
designations are includes where these names have been
used in assays descriptions (mainly from journal papers
in MCD). These cases produced 135 entries for 48
Entrez Gene IDs (EGIDs). While, in general, only small
numbers of compounds are linked to these non-canoni-
cal protein sequences (i.e. alternative splice forms of the
UniProt or RefSeq sequences corresponding to the
EGID), these are important to capture for pharmacologi-
cal differences. The human EGID total in Additional file
1 is thus 1,654.
The summed number of compounds is 1,673,803.
However, because the same compound may be assayed
against different targets in the same or different docu-
ments, the unique set is 823,179. The average is 964
and the median 41 compounds-per-target. The top-278
proteins cover 90% of the total compounds at a cut-off
of just over 1000 compounds-per-target. The summed
number of documents is 53,440. The unique totals,
12,764 journal articles and 15,170 patents, are lower
because of those that include results for more than one
target. A subset of the top-50 targets with a cut-off just
Table 1 Content statistics and stringency triages for the
combination of MCD and TGD
Entity Type Count
Total records 4442492
Unique compound structures 2856336
Unique compound structures from patents 2118101
Unique compound structures from journals 846026
Total quantitative assay results 10294189
Quantitative assay results from papers 5149097
Quantitative assay results from patents 5145092
Total documents 127330
Journal articles 79487
Patents 47843
Type-B assay results 4841851
Target names (all species) with type-B assay results 5334
Protein identifiers (all species) with type-B assay results 4043
Human proteins with type-B assay results 1736
Human gene identifiers with type-B assay results 1654
Unique compounds linked to human protein identifiers with
type-B assay results
823179
Table 2 Protein Identifier Content for Additional file 1
Entity type Count
Distinct protein names 1736
Entrez Gene ID (EGIDs) 1654
Symbols 1654
Symbol matching HGNC 1638
Splice form names 135
EGIDs with Splice forms 48
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The binned distribution for the complete Additional file
1 is given in Table 4.
Inspection of our results indicated, not unexpectedly, a
correlation between the number of compounds and
number of documents. However, this was a very broad
distribution because the extraction averages (given in
T a b l e1 )o f1 4c o m p o u n d s - p e r - p a p e ra n d4 4c o m -
pounds-per-patent, varied by at least one order of mag-
nitude for the former and two orders of magnitude for
the latter. In the following section target proteins will
thus be referred to by their rank on the basis of com-
pounds. Those within the top-50 are listed in Table 2
while any below these in the ranking are listed in Addi-
tional file 1. The triage we have used is stringent in that
it maps 28% of the compounds and 22% of the docu-
ments in Table1. Consequently, it represents target-to-
compound-to-assay mappings indicative of activity mod-
ulation of a single defined human protein target. Com-
plex targets that cannot be resolved to a single EGID (e.
g. the 20s proteosome) are not included.
Content of bona fide Drug Targets
Detailed elaboration of what constitutes a drug target is
outside the scope of this work but this has been
reviewed [20]. We, as do most descriptions for sources
of this type, use the term “target” broadly to encompass
any compound-to-protein mapping in our large dataset.
We consider the target figures and divisions given by
TTD to be a good approximation (they include a pro-
portion of authenticated one-to-many mappings) to a
set of bona fide primary targets (i.e. where the interac-
tion in vitro is mechanistically causative for the thera-
peutic effect in vivo). It should be noted that, without
inspection of the individual documents or “prior knowl-
edge”, it is difficult to discriminate within database
records per se between a bona fide drug target, a protein
assay included for the purpose of discerning compound
selectivity, off-target effects or modulating multiple tar-
gets with the same compound (i.e. polypharmacology)
[21]. This classification problem is encountered for any
large-scale collation of compound-to-protein mappings.
It cannot be discerned clearly enough to be specified in
the TCD database records because, while journal
authors will typically explain the context and objectives
of multiple assays, patent applicants often do not.
Nevertheless, it is clear from Table 2 that many of the
top-50 proteins are not (yet) successful targets of
approved drugs. A formal test was applied by determin-
ing the gene symbol intersect between Table 2 and the
185 targets of approved oral drugs from 2006 [2].
Despite there being some new targets for post-2006
approved drugs the result was only 23 in common, indi-
cating that a high compound ranking per se,i sn o t
Table 3 Ranking of top-50 targets by numbers of
compounds and documents
Rank Approved
Symbol
Entrez Gene
ID
No of
compounds
No of
documents
1 F10 2159 42869 690
2 CNR1 1268 29658 578
3 KDR 3791 27661 350
4 MAPK14 1432 24568 309
5 DRD3 1814 23405 508
6 F2 2147 22853 768
7 HRH3 11255 22748 407
8 TACR1 6869 21908 626
9 MMP13 4322 20590 315
10 CNR2 1269 19712 464
11 MMP1 4312 17525 394
12 ADORA2A 135 17181 532
13 EGFR 1956 16581 445
14 SLC6A4 6532 16571 403
15 MMP9 4318 16537 344
16 HTR6 3362 16457 504
17 MMP2 4313 16405 310
18 HTR2C 3358 15945 475
19 CRHR1 1394 15550 222
20 MC4R 4160 15084 299
21 HTR2A 3356 14622 509
22 NPY5R 4889 14547 216
23 CCR3 1232 14136 114
24 OPRM1 4988 13394 466
25 DPP4 1803 13057 308
26 REN 5972 12894 438
27 CALCRL 10203 12615 137
28 CTSS 1520 12426 177
29 CHRM3 1131 12398 412
30 CCR2 729230 12208 160
31 DRD2 1813 12050 564
32 MET 4233 11745 118
33 ADORA1 134 11644 480
34 GSK3B 2932 11283 198
35 CCR5 1234 11179 197
36 CXCR2 3579 10851 183
37 SRC 6714 10838 282
38 MCHR1 2847 10821 209
39 EDNRA 1909 10769 260
40 NR3C1 2908 10687 199
41 EDNRB 1910 10601 239
42 HTR1A 3350 10015 627
43 OPRK1 4986 9690 375
44 TACR2 6865 9676 301
45 SLC6A2 6530 9671 272
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gets-in-common across the entire list were 160. Inspec-
tion of the 25 targets not matched indicated that, in
most cases, the primary literature either included assay
data from non-human proteins (e.g. mouse or rat) or
that the cell-based receptor pharmacology assays were
not classed as “type B”. One interesting exception is
what could be classified as orphan target, tyrosine-3-
hydroxylase, TH [Swiss-Prot P07101]. While a drug was
approved for it, a-methyl tyrosine (CID 441350) many
decades ago to treat pheochromocytoma, this is now
rarely used because of side effects. Consequently, this
protein identifier has not been linked to new research
compounds within this set of extracted journal papers
and patents.
Cross-screening and Para-targets
The difficulty of discriminating primary targets from
cross-screening activities is illustrated at the top of
Table 2 for factor X, F10 [Swiss-Prot P00742] and
thrombin, F2 [Swiss-Prot P00734]. They are not only
the individual primary targets for the development of
therapeutic protease inhibitors but also, because they
are related as paralogues with a high sequence similarity
and biochemical functions, they are typically chosen as
cross-screening targets for each other. They can thus be
termed “para-targets”.W ec o n f i r m e dt h ee x t e n to f
cross-screening by determining that there were 13,504
compounds-in-common and 357 documents-in-common
(i.e. containing both thrombin and factor X inhibition
data). This has the effect of pushing each of them higher
in the compounds-per-target ranking. The second
ranked para-target pair in Table 2 is the cannabinoid
receptors 1, CNR1 [Swiss-Prot P21554] and 2, CNR2
[Swiss-Prot P34972] ranked at positions 2 and 10
respectively. These have 11,818 compounds-in-common
and 342 documents-in-common. However, there is a
difference for this pair in that antagonists have been
predominantly pursued for CNR1 but agonists for
CNR2 [22]. In addition, CNRI provides an example of
screening data derived from a specific splice variant
with unique pharmacological profile, designated as can-
nabinoid receptor 1B [Swiss-Prot P21554-3] ranked at
1216 [23]. Other para-target pairs illustrate different
aspects. For the beta amyloid cleaving enzymes BACE1
[Swiss-Prot P56817], and BACE2 [Swiss-Prot Q9Y5Z0]
clearly the former, ranked at 52, is the primary target
but there is also some cross-screening for BACE2
ranked at 338. Another series of paralogues in the table,
in order of compound ranking, are Cathepsin S, CTSS
[Swiss-Prot P25774], Cathepsin K, CTSK [Swiss-Prot
P43235], Cathepsin L, CTSL1 [Swiss-Prot P07711] and
Cathepsin G, CTSG [Swiss-Prot P08311]. These are all
cysteine proteases being explored for different diseases
but are, as one might expect, extensively cross-screened
for selectivity [24].
Anti-targets
The first anti-target (i.e. cross-screening for potential
liabilities in development) in the list, ranked at 83, is the
hERG Kv11.1 potassium channel, KCNH2 [Swiss-Prot
Q12809]. This is unsurprising considering the impor-
tance of checking for hERG inhibition [25]. Another
anti-target is the drug efflux pump, ATP-binding cas-
sette, sub-family B (MDR/TAP) member 1, ABCB1
[Swiss-Prot P08183] ranked at 313. However, a recent
analysis suggests that, while an anti-target for anticancer
agents, it can also be classified as a drug target for non-
sedating antihistamines [26].
Non-targets
The first non-target (i.e. without an established thera-
peutic context) is Trypsin, PRSS1 [Swiss-Prot Q3SY19],
ranked at 114, because of its use as a mechanistic exem-
plar for cross-screening serine protease inhibitors. A
second non-target, ranked at 261, is Albumin, ALB
[Swiss-Prot P02768]. This is due to the routine testing
of development compounds in albumin binding assays.
Strictly speaking, this protein has no activity modulation
but the compounds are nonetheless “mapped” in the
b i n d i n gs e n s e .S l i g h t l yb e l o wt h i s ,a tr a n k2 9 5 ,i st h e
Table 4 Binned distribution of compounds-per-target
Compound bin Targets above bin
10000 42
5000 95
2000 194
1051 (90% total) 278
1000 287
500 380
200 526
100 667
50 816
10 1194
2 1591
1 1736
This includes all entries in the Additional file 1.
Table 3 Ranking of top-50 targets by numbers of com-
pounds and documents (Continued)
46 ADORA3 140 9533 457
47 OPRD1 4985 9500 394
48 HSD11B1 3290 9334 151
49 ELANE 1991 9173 308
50 TRPV1 7442 8988 150
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P05067]. As an intact protein it is a non-target but
inspection of the documents reveals two distinct strate-
gies for compound testing. The first is the use of assays
that measure down-regulation of APP production in cell
lines. While this is clearly a therapeutic option to reduce
amyloid peptide deposits, there is no data to suggest
that the active compounds are actually binding APP.
The second document set specifies beta amyloid aggre-
gation antagonists (i.e. the peptide could be considered
the target). Optimisation of these compounds would
have the same therapeutic objective but would show dif-
ferent SAR. While some type of mechanistic splitting
terminology for this target classification problem could
be considered, it is important to note that the use of the
APP identifier has at least facilitated data capture.
Failed Targets
Target names can be recognised in the list where com-
pounds in Phase III trials have been publically declared as
either having safety concerns or did not show efficacy. An
example of the former, the cannabinoid receptor 1, CNR1
[Swiss-Prot P21554] is ranked second but the clinical trial
results for rimonabant (CID 104850) precluded approval
because of an increased risk of depression and suicide
[27]. During the initial drafting of this manuscript we
selected the cholesterol ester transfer protein, CETP
[Swiss-Prot P11597], ranked at 263 as a failed target exam-
ple because the progression of torcetrapib (CID 159325)
was halted [28]. However, within months, there was a
more successful phase III outcome for anacetrapib (CID
11556427) targeting the same protein [29]. Thus, the
extent to which late-stage failures constitute de-validation
remains an open question, given not only that some of
those targets can still “make it” but also that efficacy in a
pharmacogenetically stratified cohort or repurposing for
an alternative indication might still be achievable.
Nevertheless, the ability to flag likely de-validation in
the listing we have produced would be valuable. How-
ever, the capture of historical data has the limitation
that targets can achieve a high ranking if many com-
pounds have been generated during validation and
proof-of-concept studies even where these eventually
fail. In addition, negative data produced during the
research phase is less likely to be published. Our data
can be analysed on a per-year basis, so the observation
of a sustained decline in compounds (i.e. less publica-
tions on that target) can infer that validation has stalled
(data not shown).
Tractability Assessment by Molecular Frameworks
Analysis
The upper part of our compounds-per-target distribu-
tion (Table 2 and Additional file 1) provides a de facto
chemical tractability ranking. The term is used here as a
measure of the probability that a useful level of potency
for chemical modulation of the therapeutically relevant
biochemical activity of a protein can be readily achieved
in vitro. While this is likely to be related to the HTS pri-
mary hit-rate, it must be remembered that a high pro-
portion of the compounds in MCD and TGD have gone
through some hit-to-lead optimisation. We thus choose
to differentiate, on a target basis, between chemical
tractability and druggability. We consider the latter to
be the likelihood of developing compounds with appro-
priate in vivo bioavailability, efficacy and safety profiles
[30]. These two characteristics are usually related
because high chemical tractability facilitates the genera-
tion of more compound series in vitro which, in turn,
provide more optimisation options in vivo.T h em a i n
caveat with ranking targets just by compound numbers
(as in Table 3) is that, in order to be useful, a tractabil-
ity metric needs to factor-in the chemical diversity of
the compound set. For example, targets mapped to large
numbers of highly similar analogues might actually be
less tractable than those with smaller absolute com-
pound numbers but covering a broader range of
chemotypes.
We have consequently exploited the compound listing
to produce a detailed assessment of chemical diversity by
comparing molecular frameworks and scaffolds on a per-
target basis. These are well-developed concepts in medic-
inal chemistry and there are a number of ways in which
chemical structures can be abstracted. An approach, initi-
ally described by Bemis and Murcko [31], considers such
frameworks as a collection of ring systems connected by
linkers, after removing side chains. A more detailed hier-
archy was used by Xu and Johnson [32] to define Mole-
cular Equivalence Indices (MEQIs) as tools for molecular
similarity measures. These approaches have been used
for classifying and visualising compound collections
[33,34], scaffold-hopping [35], comparing small sets of
bioactive molecules [36] and large vendor libraries [37],
target selectivity [38] and to differentiate between drugs,
clinical candidate and bioactive molecules [39].
For our analysis we generated five levels of frame-
works and scaffolds using software developed at
GVKBIO:
1. Molecular Framework 1 (MF1): This is generated
from the normalised molecular structure by remov-
ing all terminal side chains. Exocyclic double bonds
(atoms connected to ring systems through multiple
bonds) and double bonds directly attached to the
linker are kept.
2. Molecular Framework 2 (MF2): This is derived
from MF1 by removing exocyclic double bonds and
double bonds directly attached to the linker.
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by ignoring all atom types other than Carbon.
4. Atom Type Scaffold (ATS): Also derived from
MF2 but ignoring bond types.
5. Graph Scaffold (GS): Also derived from MF2 but
ignoring bond types or atom types.
An example of the five levels of molecular topology
hierarchy is shown for atorvastatin (CID 60823) in
Figure 2. We applied these abstractions to the entire
compound set, on a per-target basis, and the results are
included in Additional file 1. The availability of the
molecular topology breakdown allows target tractability
to be examined in alternative ways. We have made a
comparative top-20 ranking at three levels, total com-
pounds, MF2 and GS, in Table 5.
We can see that the metalloprotease MMP1 drops
from its original compound ranking at 11 down to 19
when ranked by MF2. The cathepsin CTSS moves in
the opposite directed from 28 in the original ranking up
t o7b yM F 2 .I nt h eG Sr a n k i n gw es e et h ee l a s t a s e
ELNA rising from 49 to 20 but the kinase MAPK14
Atorvastatin (Lipitor)
Molecular Framework 1
Molecular Framework 2
Carbon Scaffold Atom Type Scaffold
Graph Scaffold
Figure 2 The molecular topology hierarchy exemplified for Atorvastatin (Lipitor).
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tractability depends significantly on the molecular fra-
mework level used for ranking.
The MF2 level is particularly relevant for medicinal
chemistry because it represents a practical scaffold level
from which substituents can be permutated for the pre-
paration of analogue series or compound libraries for
SAR studies. For this reason, we have extended the analy-
sis in Table 5 by plotting top-100 targets from Additional
file 1 (corresponding to 4680 upwards compounds-per-
target) in Figure 3.
More compounds with fewer MF2 scaffolds indicate
lower tractability (e.g. an MF2: compound ratio of 0.13
for ESR2 from a total of 6,695 compounds). A larger
ratio indicates higher tractability (e.g. 0.36 for HDAC1
from a total of 6,124 compounds). We suggest this com-
plements the ranking by compounds alone and, in this
case, clearly differentiates the relative rankings of 67 for
ESR2 and 73 for HDAC1.
The molecular scaffold results can be conceived as
collapsing the ensemble of structures mapped to a target
in progressive stages of abstraction. Thus, moving from
MF2 and GS we see a reduction as more compounds
collapse into the latter. The target trends in Figure 3 are
different for MF2 and GS. In addition, the spiked shape
of the abstractions show these can be highly target-
specific. As an example of utility, the visualisation of the
chemotype landscape for targets with very large com-
pound sets (e.g. over 10,000) is much easier when the
GS ring-type abstractions can be displayed and browsed.
The utility of using public data for examining tract-
ability before embarking on drug discovery project
directed against targets and the correlation with ligand-
based experimental assessments has recently been
pointed out [40].
Conclusions
We have triaged a commercial database to provide
human target protein identifiers ranked by the num-
bers of compounds linked to them via direct biochem-
ical assay data and the numbers of documents from
which these associations were extracted. As far as we
are aware, this is the largest published listing of this
type and presents a detailed assessment of the major
part of the human molecular target landscape that has
been, or is, under active investigation [41]. The unique
of scale of this is exemplified by comparing the
equivalent compound-to-target count for F10 in
ChEMBL of 5,871 against 42,869 in this work. This is
because the process includes the extraction com-
pounds and data not only from journal articles but
also from patents.
Table 5 Top-20 target rankings by compound count and molecular frameworks
Cmpd ranking Target symbol MF2 ranking Target symbol GS ranking Target symbol
1 F10 1 F10 1 F10
2 CNR1 7 HRH3 7 HRH3
3 KDR 2 CNR1 3 KDR
4 MAPK14 6 F2 6 F2
5 DRD3 3 KDR 2 CNR1
6 F2 5 DRD3 24 OPRM1
7 HRH3 28 CTSS 20 MC4R
8 TACR1 8 TACR1 5 DRD3
9 MMP13 10 CNR2 8 TACR1
10 CNR2 12 ADORA2A 29 CHRM3
11 MMP1 4 MAPK14 28 CTSS
12 ADORA2A 29 CHRM3 26 REN
13 EGFR 9 MMP13 10 CNR2
14 SLC6A4 26 REN 4 MAPK14
15 MMP9 24 OPRM1 12 ADORA2A
16 HTR6 23 CCR3 31 DRD2
17 MMP2 20 MC4R 38 MCHR1
18 HTR2C 17 MMP2 37 SRC
19 CRHR1 11 MMP1 16 HTR6
20 MC4R 25 DPP4 49 ELANE
Columns 1 and 2 are the compound count ranking, columns 3 and 4 show the molecular framework 2 (MF2) ranking and colums 5 and 6 show the graph
scaffold (GS) ranking.
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Page 8 of 11Nevertheless, there are limitations (beyond our triage
choices) that preclude this being a complete capture of
the available data. The first is that in the PubChem-
BioAssay database, while the direct assay methods may
have been published as documents, the compound
structures, protein identifiers and result sets are only
instantiated in silico [42,43]. The second limitation is
the necessity to cap the number of examples extracted
from a patent. The third is that patent data extraction is
currently limited to the “big ten” target classes and Eng-
lish language applications (but efforts are underway at
GVKBIO to expand this). The fourth is journal selection
as opposed to all journals. Whilst these pragmatic
constraints may bias the extractions, we propose that, in
SAR terms, they are selective for higher quality data.
Our complete set of results include many proteins that
would not be considered bona fide drug target candi-
dates, not only for the reasons already pointed out in
the review of the list, but also by being in the tail of the
compound distribution. However, the inclusion of even
the singletons (one compound from one publication) is
useful not only because they have been authenticated by
expert extraction but also both the target and the com-
p o u n dm a yh a v eaw i d e rs e to fr elationships using dif-
ferent species and/or assay type restrictions. Imposing
any cut-off for “target likelihood” is clearly arbitrary but
A 
 
 
B 
Figure 3 Sorted MF2 to number of compounds ratio (a) and Graph Scaffold to number of compounds ratio (b).T h i si sp l o t t e df o ra l l
targets with more than 4869 compounds from Additional file 1.
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Page 9 of 11taking, a lower limit of 20 compounds-per-target still
covers just over 1000 proteins. This brings it into con-
gruence with the data-supported target count of 836
human proteins for which moderately potent small-
molecule chemical starting points had previously been
reported [44].
Our breakdown of the compound sets into molecular
scaffolds provides a useful measure of target-specific che-
mical tractability. Nevertheless, we can point out factors
that may be skewing the ranking upwards. The first is the
cross-screening effect already mentioned where many
compounds mapped to a target are not being optimised
for that target. A second effect is that resources assigned
to target projects are determined by factors such as market
potential, competitive positioning and unmet clinical need.
This skews the distribution away from an objectively neu-
tral ranking of tractability per se towards those targets the
research community is collectively “working hardest” on.
This intense focus also produces patent thickets (in the
sense that many of the synthetically feasible chemotypes
and analogues that can bind to a particular active site have
already been claimed) that will also drive the expansion of
chemical diversity for popular targets.
Readers are encouraged to explore their own addi-
tional analyses for Additional file 1. These could include
generating intersects and differences with, for example,
disease associated protein lists or other target protein
lists extracted from public databases. In addition, the
proteins could be further divided by sub-family and/or
the existence of representative 3D structures in PDB.
Further large-scale studies of the target landscape analo-
gous to those reported here will be important as drug
discovery continues to expand towards new therapeutic
areas, new targets, broader cross-screening activities,
repurposing and polypharmacology.
Endnotes
Protein designations first used in the text are given as their
common name followed by the HGNC approved human
gene symbol as used in the result tables. These are fol-
lowed by the Swiss-Prot ID. Drug names are accompanied
by their PubChem compoundidentifiers (CIDs).
Additional material
Additional file 1: Additional material. A list of proteins with names,
symbols and Entrez Gene identifiers (Microsoft EXCEL). It also includes
compound and document counts and the molecular framework
breakdown for the compound sets.
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